[Mortality after administration of human albumin to critically ill patients with hypovolemia. An analysis of a systematic Cochrane review].
A systematic Cochrane review strongly suggested that the administration of human albumin to critically ill patients with hypovolaemia increases mortality. This review has been widely criticised and the aim of the present paper was to analyse the original studies with regard to 1) the randomisation procedure, 2) the blinding procedure, 3) the indication of treatment, 4) whether treatment was clearly defined and consistent, 5) how normovolaemia was defined, and 6) the length of the follow-up period. None of the twelve studies analysed fulfilled common criteria in relation to evidence-based medicine. Consequently, there is no scientific evidence to support the conclusion that human albumin administered to critically ill patients with hypovolaemia increases the mortality. Thus, the validity and quality control of systematic Cochrane reviews may be questioned.
Jørgensen
B G
BG
H:S Rigshospitalet, HovedOrtoCentret, anaestesi- og operationsklinikken 4132 og Abdominalcentret, intensiv afdeling, ITA 4131.
Rasmussen
L S
LS
Heslet
L
L
D016638:Critical Illness; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D020896:Hypovolemia / Q000401:mortality / Q000628:therapy*; D015201:Meta-Analysis as Topic; D012709:Serum Albumin / Q000008:administration & dosage*
D012709:Serum Albumin
Mortalitet efter humant albumin hos kritisk syge patienter med hypovolaemi. En analyse af et systematisk Cochrane-review.